4 Small Biotech M&A Targets for Gilead
Investors and analysts had been encouraging Gilead to acquire something for a long time, so they were mostly happy when it bought Kite Pharma in September. Source: BioSpace
Teva Surges After Warren Buffett's Berkshire Reports $358M Stake
Teva got a nice shot in the arm after reports that billionaire investor Warren Buffett took a stake in the company. Source: BioSpace
J&J Wins FDA Nod for Erleada, the First Drug for Nonmetastatic Prostate Cancer
Janssen got a little love from the FDA on Wednesday. Source: BioSpace
Vertex Nixes Three Planned Phase III CF Trials in France
Vertex has declined to comment, but BioCentury received a copy of the letter the company sent to laboratories explaining. Source: BioSpace
GT Biopharma Promotes COO to Top Post, Effective Immediately
Mr. Cross has held the position of President and COO of GTBP since November 16, 2017. Source: BioSpace
Meet the Little-Known Chinese CAR-T Biotech Up More Than 500% Since June 2017
The company reported positive results from early studies in 35 patients with a type of blood cancer last year. Source: BioSpace
FDA Berates Bayer for Inadequate Cleaning, QC Questions at HQ
The company is addressing the FDA’s complaints regarding manufacturing practices, which stem from a routine inspection in January, Source: BioSpace
Jobs Affected as ImmunoGen Winds Down Ops at Massachusetts Facility
ImmunoGen gave a pipeline progress report and 2017 operating results last week. Source: BioSpace
Japan's Astellas Pays $102.5M for U.S. Biotech Universal Cells
Astellas will gain Universal Cells' proprietary Universal Donor Cell technology to create cell therapy products that do not require HLA matching. Source: BioSpace
FDA Declares Pfizer's Atopic Dermatitis Drug a Breakthrough
The Phase 3 program is the first trial in the JAK1 Atopic Dermatitis Efficacy and Safety global development program. Source: BioSpace
- Go to the previous page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- …
- 288
- Go to the next page